Updated treatments of castration-resistant prostate cancer.
- Author:
Yun-fei WEI
;
Xiao-jian GU
;
Qing-yi ZHU
- Publication Type:Journal Article
- MeSH:
Androgen Antagonists;
Bone Neoplasms;
prevention & control;
Humans;
Immunotherapy;
Male;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms, Castration-Resistant;
therapy;
Quality of Life
- From:
National Journal of Andrology
2016;22(5):455-461
- CountryChina
- Language:Chinese
-
Abstract:
The diagnosis and treatment of prostate cancer are being improved due to the popularized screening of prostate specific antigen. Advanced prostate cancer, in spite of its response to androgen deprivation therapy, may finally develop into castration-resistant prostate cancer (CRPC) and shorten the overall survival of the patients. Many efforts have been made by worldwide researchers for new approaches to the management of CRPC, including new hormonal therapy, cytotoxic chemotherapy, immunotherapy, and bone metastasis-targeted therapy. This paper reviews the emerging agents undergoing clinical evaluation and drugs that have received approval for the treatment of CRPC in order to provide doctors and patients with more treatment options for CRPC and improve the overall survival rate and quality of life of the patients.
